Utah Just Legalized Autonomous AI Prescribing of Antidepressants — No FDA, No Human Refill
A state regulatory sandbox just routed autonomous AI prescribing — including SSRIs — around the FDA entirely.
In January, the Utah Department of Commerce signed a regulatory mitigation agreement letting an autonomous AI agent built by Doctronic renew prescriptions for Utahns with chronic conditions — including SSRIs — without a licensed prescriber signing each refill. The pilot covers 192 drugs treating chronic conditions such as hypertension, diabetes, and depression. No FDA clearance. No SaMD pathway. A state contract, and the unprofessional-conduct statutes step aside.
The structural argument for the pilot is real, and worth saying plainly. Renewals are unreimbursed administrative work, patients in rural counties wait weeks to see a prescriber, and the medications on the list don't change much year to year.
Prescription renewals account for roughly 80% of all medication activity, and the gap between "I need my lisinopril" and "I can get an appointment" is where adherence breaks down. The sandbox is the Office of Artificial Intelligence Policy's instrument for testing that hypothesis under contract rather than statute.
What makes this notable for anyone watching clinical AI is the structural inversion. The litigation and AG actions everyone is tracking — Texas going after Character.AI, the Raine v. OpenAI complaint, the wave of cases described in previous coverage of the new medical-advice liability theory — all target AI systems that claim to be clinicians without authorization. Utah did the opposite. It authorized one. The state has embarked on the first test of artificial intelligence as an autonomous clinical decision-maker under a regulatory suspension paradigm.
The safeguards are not nothing. Human physicians will review the AI's output for the first 250 patients, an automatic escalation protocol refers complex cases to clinicians, and Doctronic is contractually prohibited from using patient data for other purposes. Patients must be told they are interacting with AI. The system excludes controlled substances, ADHD medications, injectables, and drugs requiring lab monitoring. Doctronic carries malpractice coverage explicitly extended to the AI.
The clinical hesitations are also not nothing. SSRIs are on the renewal list. The standard outpatient practice for someone stable on an SSRI is a periodic check-in — partly for side effects, partly because that visit is where suicidal ideation, alcohol use changes, and new stressors get surfaced. A renewal portal that asks about symptoms in a chatbot does not replicate that. Autonomous AI renewal risks losing an important clinical touchpoint for patients to receive preventive care. Whether that loss is offset by the patients who get medication at all because the friction dropped is an empirical question the pilot is, in fact, designed to answer.
The harder question is jurisdictional. A NEJM Perspective by Gerke, Parikh, and Cohen lays out the legal and clinical issues, and Doctronic is already in talks with Arizona, Texas, and Missouri. If autonomous prescribing scales through state sandboxes, the FDA's Software-as-a-Medical-Device framework becomes the regulator that arrived late to its own jurisdiction. The chatbot-safety conversation has been arguing about whether AI can act like a clinician. Utah just answered a different question: whether a state can simply say yes.
The translation problem here is the one Metonym was built around. A 99%-concordance number generated against urgent-care vignettes is not the same evidence as deployment performance on a patient renewing an SSRI in month nine of a depressive episode — and the absence of an independent evaluation protocol is exactly the gap a clinical-grade evaluation methodology is designed to close.
Metonym Clinical AI Intelligence — regulatory analysis at the intersection of clinical evaluation and AI safety. Produced under the Metonym Standard. Informational only — not legal advice, not clinical advice.